Giant cell arteritis (GCA) is a primary vasculitis of large and medium-sized arteries. It is the most common vasculitis affecting the elderly. GCA involves the cranial ramifications of the carotid arteries and classically presents with cranial symptoms such as headache or jaw claudication. Aortitis can occur, and cases of mesenteric ischemia have been reported. Diagnosing can be challenging, and subclinical mesenteric ischemia in GCA may be more prevalent than previously recognized.
A 70-year-old woman went to the emergency room complaining of a new-onset pan-cranial headache and a sensation of periorbital fullness with a blurred vision of the right eye. The questionnaire revealed increased fatigability with scalp sensitivity, jaw claudication, nausea, and mild epigastric pain.
Initial workup revealed augmented erythrocyte sedimentation rate and C-reactive protein. The presumptive diagnosis was GCA. The patient was initiated on prednisone, and a temporal artery biopsy was requested. Unfortunately, the patient discontinued taking prednisone because of significant nausea and was prescribed on intravenous (IV) methylprednisolone.
An abdominal computed tomography angiogram excluded any infiltration or stenosis of the primary vascular trunk of the abdominal aorta. But a significant thickening of the wall of the descending thoracic aorta was observed.
When on prednisone 1 mg/kg, the abdominal pain continued to worsen. A simple abdominal radiograph detected free air, and a CT scan confirmed bowel perforation.
Emergent laparotomy identified and resected a continuous 100 cm of necrosis of the small intestine. The mesenteric arteritis slides demonstrated multifocal mucosal ischemia, characterized by a transmural lymphohistiocytic infiltrate, which included rare multi-nucleated giant cells.
After the second surgery, addressing an anastomotic leak, vasopressors support, and slow weaning of high doses IV corticosteroids. The patient was discharged with a daily dose of prednisone and followed as an outpatient.
This case underlines the systemic nature and potentially unpredictable clinical course of GCA. We described the histopathologic features of mesenteric involvement and summarized the state of the literature with a focus on management strategies.
A 70-year-old woman, only with a history of high blood pressure, went to the emergency room for a pan-cranial headache. Earlier the same day, she had an episode of lightheadedness followed by a fall and head trauma during a training session at the gymnasium, without loss of consciousness, convulsions, or post-ictal period. Upon arrival, the patient had a 5/10 pulsatile pan-cranial headache with neck pain, without focal neurological symptoms, which were relieved by treatment with acetaminophen. The patient reported a sensation of periorbital fullness with a blurred vision of the right eye, fluctuating over a couple of weeks. She also complained of fatigue, nausea, and epigastric pain that had been progressing for a few days.
Initial assessment revealed tachycardia (110 bpm) with normal blood pressure (131/83 mmHg), without tachypnea or fever, or orthostatic hypotension. The remaining physical examinations including neurologic exam, visual fields, and acuity, were unremarkable. Initial workup revealed a leukocytosis of 15.8 with significant neutrophilia (13.75), thrombocytosis (619), and normal hemoglobin (119). Serum electrolytes and liver function tests were in normal range. A cranial computed tomography (CT) scan was performed, which revealed a mild leukoencephalopathy without focal lesions. Electrocardiogram was in sinus rhythm.
An ophthalmology consultation reported narrow, closable angles and evolving cataracts without convincing evidence of temporal arthritis. However, clinical suspicion of the latter remained, as further workup revealed an elevated ESR of 90 mm/h and a C-reactive protein (CRP) at 361.5 mg/L. Consultation by internal medicine noted scalp sensitivity and a history of mandibular pain when chewing. The neurological examination and temporal artery pulse remained normal. With a presumptive diagnosis of temporal arteritis, a temporal biopsy was ordered. The patient was initiated on prednisone (60 mg orally per day) and was discharged with a follow-up three days later.
At the follow-up, the patient reported that she was unable to start prednisone because of nausea. She was immediately admitted for intravenous (IV) corticosteroid therapy for 48 hours and was initiated on methylprednisolone 40 mg IV q6h from prednisone. A CT angiogram excluded any significant infiltration of peri-aortic fat and any stenosis of the main vascular trunks of the abdominal aorta. However, aortitis remained in the differentials as a significant thickening (3 mm) of the wall of the descending thoracic aorta was observed (Figure 1).
Figure 1. Cross-sectional view of the circumferential thickening of the aortic wall, as seen in the thorax CT angiography.
Pathology of the temporal artery returned with a diagnosis of active arteritis with luminal thrombosis. However, no giant cells were observed (Figure 2).
Figure 2. Histologic images (hematoxylin and eosin stain), showing intense transmural lymphohistiocytic inflammation and luminal stenosis of the temporal arteries.
The patient demonstrated a slight initial improvement regarding her general well-being on corticosteroids with a minimal reduction in abdominal pain and a regain of energy. In the days that followed, nausea persisted with frequent bilious vomiting and no bowel movement. Plain abdominal radiographs were compatible with subocclusive phenomena and no sign of constipation. Repeat laboratory tests demonstrated a reduction in CRP from 361.5 to 156.0 mg/L, and normal lactate reassured the treating team of any significant ischemic event.
Abdominal pain and distension continued to worsen, and by day 10 of hospitalization, a simple abdominal radiograph demonstrated free air. An emergent CT scan was compatible with a bowel perforation with severely collapsed ileal loops. However, the site of the perforation could not be determined radiologically. So, an emergent laparotomy was performed, and a continuous 100 cm section of the necrotic small intestine was identified and resected, with a nodular appearance and numerous apparent microperforations.
Figure 3(a,b) shows the histologic examination (hematoxylin and eosin staining) of the resected small bowel. Results showed mesenteric arteritis associated with multifocal mucosal ischemia. Figure 4 shows the arteritis slides with a transmural lymphohistiocytic infiltrate including rare multinucleated giant cells.
Figure 3. Histologic images of intense transmural lymphohistiocytic inflammation and luminal stenosis of the mesenteric arteries (a). Representative section of the small ischemic bowel, showing complete loss of the intestinal epithelium and villi in the area fed by affected arteries (between dotted lines) (b).
Figure 4. Rare intramural multinucleated giant cells (arrow) identified within the inflamed mesenteric arteries.
A complete vasculitis panel indicated no significant titers of antineutrophil cytoplasm antibodies, rheumatoid factors, and anti-nuclear antibodies. After the surgical resection, the patient received 500 mg/day of methylprednisolone in addition to aggressive rehydration and vasopressor support. Unfortunately, an anastomotic leak occurred 2 weeks later, requiring the pose of a temporary ileostomy while on prednisone 60 mg orally per day tapering doses. After a few weeks, the patient successfully went through reanastomosis and is currently at home on weaning prednisone doses.
GCA is a primary vasculitis of large and medium-sized arteries, with an incidence of approximately five per 100,000 people ≥50 years old. The incidence increases with age, and it’s three times more common in women than men.1
GCA commonly involves the cranial ramifications of the carotid arteries, such as the temporal arteries, but can also involve the aorta. While the most feared complication of GCA (permanent blindness) is irreversible, involvement of the mesenteric arteries can be life-threatening. The mesenteric involvement by GCA is rare, but it is associated with mortality rates reaching 70%.2
In a meta-analysis of 17 studies, the most frequent causes of death in GCA were cardiovascular disease (39%), cerebrovascular disease (14%), infection (13%), and malignancy (12%). However, no difference in the long-term mortality in GCA was observed at the populational level. Deaths attributed to gastrointestinal (GI) problems comprised 4% in this review. Increased mortality in GCA because of GI (ulcer/hemorrhagic) bleeding was also reported.3
While mesenteric ischemia can be the presenting manifestation of GCA, it also can develop during ongoing treatment. From a series of 28 histologically proven mesenteric-GCA cases, 12 were diagnosed before the appearance of GI symptoms. Mesenteric ischemia occurred either soon after initiation of steroid therapy (n = 6; mean time to onset after starting steroid, 12±11 days) or with a low-dose steroid regimen (n = 6; dosages, 0–10 mg/day).4
From case reports, it was noted that the clinical manifestations of GCA-associated mesenteric ischemia and biological markers (CRP), are very nonspecific. Previous studies reported that the mesenteric vasculature has an extensive network of collateral vessels that are vital for ensuring visceral perfusion. During the occlusion of a major vessel, these collateral vessels can dilate and maintain perfusion of the entire adjacent territory.2 This might explain why the serum lactate levels remained normal in this case of mesenteric ischemia with extensive abdominal wall necrosis. Furthermore, the patient in this study presented only a few abdominal symptoms until the development of an acute abdominal event, suggesting the increased prevalence of subtle or subclinical mesenteric ischemia in patients with GCA than previously recognized.
As mesenteric involvement is rare, one must explore the differential diagnosis when faced with this unusual presentation, including polyarteritis nodosa (PAN) and the ANCA-associated vasculitides. In this case, we considered the latter unlikely given the ANCA negativity, lack of eosinophilia, and lack of typical histopathologic findings. Although PAN typically affects small- and medium-sized arteries and arterioles, there are reported cases of the temporal arteries affected by PAN. No reference standard test to diagnose PAN is available. The PAN diagnosis often rests on the appropriate clinical context and the classic histopathology findings of segmental transmural inflammation of muscular arteries with fibrinoid necrosis.5 In contrast to PAN, GCA typically lacks fibrinoid necrosis and contains scattered multinucleated giant cells.
Takayasu arteritis is extremely rare in North America but was a possible differential. It can be difficult to distinguish from GCA, and the diagnosis relies heavily on the demographics of the presenting patient, as it predominantly afflicts young women of Asian or Middle Eastern descent.7 The histopathologic features of Takayasu arteritis overlap with GCA. The inflammatory infiltrate is more severe in the adventitia and outer half of the arterial media, wheras the opposite is true for GCA.
While the lack of giant cells in the temporal artery biopsy put the initial diagnosis of GCA into question, it was still favored over PAN and Takayasu arteritis from a clinical standpoint in our case. Given the patient was admitted with the initial presentation of a headache, monocular visual disturbances, jaw claudication, skin changes, and polyneuropathy. Moreover, it’s well documented that multinucleated giant cells can be absent on temporal artery biopsy in up to 50% of the patients with GCA.6
Minimal data exist concerning the medical treatment of mesenteric ischemia in GCA. According to the recommendations of EULAR 2018, a reasonable dose would be prednisone 40 to 60 mg/day or equivalent. For a fleeting amaurosis or acute vision loss, methylprednisolone 0.25 to 1 g/day for 3 days should be considered.8
Adjunctive therapy should be used in selected patients with GCA (refractory or relapsing disease, an increased risk for glucocorticoid-related adverse effects or complications) using tocilizumab, a humanized monoclonal antibody against IL-6 receptors. However, it has been associated with an increased incidence of GI perforation and hence was avoided in our situation.9
Other lines of treatment are controversial, such as antiplatelets, and few guidelines currently recommend their use. Statins failed to demonstrate any benefit in GCA.10 Methotrexate may be used as an alternative but was not tested in our patient.8
In summary, this case illustrates the systemic nature and potentially unpredictable clinical course of GCA despite early recognition and treatment of the disease. Mesenteric involvement by GCA may well be underrecognized, which underlines the importance of having a low threshold for vascular imaging in the context of bowel symptomatology. Given the potentially grave consequences of this disease, aggressive initial treatment (intravenous methylprednisolone) should be considered not only in cases with significant visual impairment but also when there is a high index of suspicion of mesenteric ischemia.
1. Ing EB, Lahaie Luna G, Pagnoux C, et al. The incidence of giant cell arteritis in Ontario, Canada. Can J Ophthalmol 2019;54(1):119–24. https://doi.org/10.1016/j.jcjo.2018.03.002
2. Scola CJ, Li C, Upchurch KS. Mesenteric involvement in giant cell arteritis. An underrecognized complication? Analysis of a case series with clinicoanatomic correlation. Medicine 2008;87(1): 45–51. https://doi.org/10.1097/MD.0b013e3181646118
3. Hill CL, Black RJ, Nossent JC, et al. Risk of mortality in patients with giant cell arteritis: a systematic review and meta-analysis. Semin Arthritis Rheum 2017;46(4):513–9. https://doi.org/10.1016/j.semarthrit.2016.08.015
4. Sujobert P, Fardet L, Marie I, et al. Mesenteric ischemia in giant cell arteritis: 6 cases and a systematic review. J Rheumatol 2007;34(8):1727–32. https://pubmed.ncbi.nlm.nih.gov/17611981/
5. Généreau T, Lortholary O, Pottier MA, et al. Temporal artery biopsy: a diagnostic tool for systemic necrotizing vasculitis. French Vasculitis Study Group. Arthritis Rheum 1999;42(12): 2674–81. https://doi.org/10.1002/1529-0131(199912)42:12<2674::AID-ANR25>3.0.CO;2-A
6. De Golovine S, Parikh S, Lu L. A case of polyarteritis nodosa presenting initially as peripheral vascular disease. J Gen Intern Med 2008;23(9):1528–31. https://doi.org/10.1007/s11606-008-0683-0
7. Mirault T, Messas E. La maladie de Takayasu. Rev Med Interne 2016;37(4):223–9. https://doi.org/10.1016/j.revmed.2015.12.024
8. Hellmich B, Agueda A, Monti S, et al. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 2020;79(1):19–30. https://doi.org/10.1136/annrheumdis-2019-215672
9. Monemi S, Berber E, Sarsour K, et al. Incidence of gastrointestinal perforations in patients with rheumatoid arthritis treated with tocilizumab from clinical trial, postmarketing, and real-world data sources. Rheumatol Ther 2016;3(2):337–52. https://doi.org/10.1007/s40744-016-0037-z
10. Ponte C, Rodrigues AF, O’Neill L, Luqmani RA. Giant cell arteritis: current treatment and management. World J Clin Cases 2015;3(6):484. https://doi.org/10.12998/wjcc.v3.i6.484